SFJ Pharmaceuticals
Business Services · California, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
4682 Chabot 10034 Dr, Pleasanton, Califo...Website
www.sfj-pharma.comRevenue
$12.2 MillionIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
1
1
1
1
1
1
About SFJ Pharmaceuticals
SFJ Pharmaceuticals specializes in providing risk capital, expertise, and resources for accelerated clinical development in the biopharmaceutical sector. They offer comprehensive support for clinical trials, including funding, trial design, and execution, while assuming 100% of clinical development risk. Their clients primarily include clinical-stage biopharmaceutical companies seeking to develop novel therapies across various indications. With a proven track record of successful partnerships and a global reach, SFJ aims to fill operational and funding gaps in the drug development process.Explore more
SFJ Pharmaceuticals Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is SFJ Pharmaceuticals your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Click to see if SFJ Pharmaceuticals had a recent Job posting/layoffs
Congratulate Masked Content for being promoted to Masked Content at SFJ Pharmaceuticals
Product Launch: Get notified when SFJ Pharmaceuticals launches new products
Check if SFJ Pharmaceuticals has recently received funding, and reach out quickly before it becomes old news!
Funding: Get notified immidiatlly once SFJ Pharmaceuticals has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Earning: See what the market has to say on SFJ Pharmaceuticals recently announced quarterly report
SFJ Pharmaceuticals, which may be a good buyer, showed buying intent in Masked Content Topic
Check out if SFJ Pharmaceuticals is spiking on competitors!
Website visits: Recent activity has been detected on your website
Recommended Actions
Reach out to Masked Content who joined SFJ Pharmaceuticals as Masked Content
Find 3 more new buyers
Compare Similar Companies to SFJ Pharmaceuticals
Compare insights from companies similar to SFJ Pharmaceuticals, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
SFJ Pharmaceuticals is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
SFJ Pharmaceuticals is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about SFJ Pharmaceuticals.
SFJ Pharmaceuticals Tech Stack
A closer look at the technologies used by SFJ Pharmaceuticals
SFJ Pharmaceuticals News & Media
FDA has accepted a BLA for bentracimab, the first and only ticagrelor reversal agent, for filing and priority review
Pleasanton, CA and Philadelphia, PA, Aug. 02, 2024 (GLOBE NEWSWIRE) -- SFJ Pharmaceuticals, (SFJ), Sponsor of the bentracimab Biologics License Application (BLA), and SERB Pharmaceuticals (SERB), who acquired exclusive US rights to bentracimab from SFJ and will commercialize bentracimab in the United States, announced today that the US Food and Drug Administration (FDA) has accepted the bentracimab BLA for filing and priority review with a target action date in Q1 of 2025.SERB Pharmaceuticals and SFJ Pharmaceuticals announce a U.S. partnership for bentracimab, a ticagrelor reversal agent
PHILADELPHIA and SAN FRANCISCO, May 11, 2023 (GLOBE NEWSWIRE) -- SERB Pharmaceuticals, a global specialty pharmaceutical company, and SFJ Pharmaceuticals, a global drug development company, announce that SERB has acquired exclusive US rights to the ticagrelor reversal agent bentracimab from SFJ.SFJ Pharmaceuticals Announces Closing of Transfer of Bentracimab Assets from PhaseBio Pharmaceuticals
SAN DIEGO--(BUSINESS WIRE)--SFJ Pharmaceuticals (“SFJ” or the “company”) today announced the closing of the sale and transfer of assets related to Bentracimab from PhaseBio Pharmaceuticals, Inc. (“PhaseBio”) to SFJ. The sale and transfer was approved on December 31, 2022 by the U.S. Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”), where PhaseBio’s chapter 11 case has been pending since October 2022. Since 2020, SFJ and PhaseBio have worked on co-developing Bentracimab (foNektar Secures Collaborative Deal with SFJ to Advance Head and Neck Cancer Therapy
Nektar Therapeutics has entered into a financing and co-development collaboration with SFJ Pharmaceuticals which will advance the development of investigational CD122-preferential IL-2–pathway agonist bempegaldesleukin for head and neck cancer.
Read more news
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding SFJ Pharmaceuticals
Sign Up For FreeTo access detailed company insights
SFJ Pharmaceuticals specializes in providing risk capital, expertise, and resources for accelerated clinical development in the biopharmaceutical sector. They offer comprehensive support for clinical trials, including funding, trial design, and execution, while assuming 100% of clinical development risk. Their clients primarily include clinical-sta... Read More
